Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.055.494 ![]() |
Chemical and physical data | |
Formula | C21H27N |
Molar mass | 293.454 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.[2][3][1]
While its exact mechanism of action is not well characterized,[2] it is believed to be an NMDA receptor antagonist,[4][5] but also promoting the synthesis of dopamine.[6]
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[6][7]
((cite journal))
: CS1 maint: multiple names: authors list (link)
Dopaminergics |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Anticholinergics | |||||||||||
Others | |||||||||||
|